Individual experiences vary depending on treatment goals, overall health, activity level, and other factors
Two are FDA-approved specifically as injectable weight loss medications: Saxenda (liraglutide) approved in 2014, injected once daily
Most relevant peptides: KPV for skin and mucosal anti-inflammatory effects Thymosin alpha-1 for immune regulation (notably, the Pica study specifically included psoriatic arthritis patients) BPC-157 for tissue repair in joint involvement KPV is particularly relevant for psoriasis because of its calming effects on skin inflammation
Users commonly report 2.5-5mg per day via subcutaneous injection, often once daily or split
British Journal of Anaesthesia
Injections can be administered in the abdomen, thigh, or upper arm